Larimar Therapeutics to Attend Upcoming Investor Conferences

BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will join in 1×1 investor meetings at the Wells Fargo Healthcare Conference, taking place September 4-6, 2024 in Boston, MA and the HC Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to utilize its intracellular delivery platform to design other fusion proteins to target other rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
(212) 915-2569